Literature DB >> 33579951

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.

Gaia Griguolo1,2, Maria Vittoria Dieci3,4, Laia Paré5,6, Federica Miglietta1,2, Daniele Giulio Generali7, Antonio Frassoldati8, Luigi Cavanna9, Giancarlo Bisagni10, Federico Piacentini11, Enrico Tagliafico12, Katia Cagossi13, Guido Ficarra14, Aleix Prat5,6, Pierfranco Conte1,2, Valentina Guarneri1,2.   

Abstract

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

Entities:  

Year:  2021        PMID： 33579951     DOI： 10.1038/s41523-021-00223-x

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN： 2374-4677


  1 in total

1.  Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

Authors:  Yuichiro Miyoshi; Tadahiko Shien; Akiko Ogiya; Naoko Ishida; Kieko Yamazaki; Rie Horii; Yoshiya Horimoto; Norikazu Masuda; Hiroyuki Yasojima; Touko Inao; Tomofumi Osako; Masato Takahashi; Nobumoto Tomioka; Yumi Wanifuchi-Endo; Mitsuchika Hosoda; Hiroyoshi Doihara; Hiroko Yamashita
Journal:  Oncol Lett       Date:  2018-12-19       Impact factor: 2.967
  1 in total
  1 in total

1.  Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.

Authors:  Elahe Shenasa; Elisabeth Specht Stovgaard; Maj-Britt Jensen; Karama Asleh; Nazia Riaz; Dongxia Gao; Samuel Leung; Bent Ejlertsen; Anne-Vibeke Laenkholm; Torsten O Nielsen
Journal:  Cancers (Basel)       Date:  2022-08-05       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.